Development asset linked to MoonLake Immunotherapeutics in public FDA and regional records.
pharma · hidradenitis suppurativa (HS) · Hidradenitis Suppurativa · MLTX
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Dorfstrasse, 29, Zug 6300, CH HQ
2021 Founded
133 Employees
Public company Type
MLTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Dorfstrasse, 29, Zug 6300, CH
- Founded
- 2021
- Employees
- 133
- Programs
- 13
- Drugs
- 11
- Patents
- 0
MoonLake Immunotherapeutics pipeline
Portfolio lens on 11 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
MoonLake Immunotherapeutics drug portfolio — 11 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
apomorphine
Genito-urinary system and sex hormones (G04)Genito-urinary system and sex hormones (G04) compound in MoonLake Immunotherapeutics's portfolio. Mechanism: D2-like dopamine receptor agonist.
- Mechanism
- D2-like dopamine receptor agonist
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to MoonLake Immunotherapeutics in public FDA and regional records.
-
Development asset linked to MoonLake Immunotherapeutics in public FDA and regional records.
-
Development asset linked to MoonLake Immunotherapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
risankizumab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in MoonLake Immunotherapeutics's portfolio. Molecular target: Interleukin-23.
- Target
- Interleukin-23
- Mechanism
- Interleukin-23 inhibitor
-
Development asset linked to MoonLake Immunotherapeutics in public FDA and regional records.
-
Development asset linked to MoonLake Immunotherapeutics in public FDA and regional records.